Abstract
The Indian pharmaceutical sector is large and has the potential of a global leader for low-priced high-quality drugs. The new patent regulations had a strong impact on the drug industry in India. There is a serious decline in the number of pharma patents recently after compulsory licensing for drugs was implemented in India. While regulations are meant for reducing the prices of essential drugs, there are investment-related issues when a patent is subjected to voluntary licensing. The present study focuses on three phases in pharmaceutical patenting identified by analysing the major patent databases and the potential shift in pharma patenting sector from acute to lifestyle disease-based drugs. The recent trend identified in the pharma patenting sector in India is quite unusual and unreported so far.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
